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A novel protoparvovirus species, related genetically to hu-
man bufaviruses, was identified in dogs with respiratory 
signs. The canine bufavirus was distantly related to the well-
known canine protoparvovirus, canine parvovirus type 2, 
sharing low amino acid identities in the nonstructural protein 
1 (40.6%) and in the capsid protein 1 (33.4%). By screening 
collections of fecal, nasal, and oropharyngeal samples ob-
tained from juvenile dogs (<1 year of age), canine bufavirus 
DNA appeared as a common component of canine virome. 
The virus was common in the stool samples of dogs with or 
without enteric disease and in the nasal and oropharyngeal 
swab samples of dogs with respiratory signs. However, the 
virus was not detected in nasal and oropharyngeal swab 
samples from animals without clinical signs.
Parvoviruses (family Parvoviridae) are small, nonenvel-oped viruses of 25–30 nm in diameter, with an icosahe-
dral capsid. The genome is a single-strand DNA of 4.5–5.5 
kb (1) with complex hairpin structures at the 5′ and 3′ ends. 
The genome is predicted to encode 3 or 4 proteins: non-
structural (NS) 1, nucleoprotein (NP) 1, and viral protein 
(VP) 1 and 2.
Parvoviruses have long been known in dogs, since the 
identification of canine minute virus, or canine parvovirus 
(CPV) type 1 (CPV-1; genus Bocaparvovirus), in 1967 
from the fecal samples of healthy dogs (2). CPV-1 infec-
tion is responsible for reproductive disorders and occasion-
ally for respiratory and gastrointestinal signs in young pup-
pies (3). A second CPV (CPV-2; genus Protoparvovirus) 
was reported in the 1970s in Europe and North America 
in puppies with signs of hemorrhagic gastroenteritis and 
myocarditis (4). CPV-2 is currently regarded as the ma-
jor causative agent of severe gastroenteritis in puppies and 
is included in canine core vaccination schedules globally 
(5). In 2011, a second canine bocaparvovirus (CBoV) was 
identified from nasal swabs of healthy and sick dogs (6); a 
third species of CBoV was identified in 2013 in the liver 
of a dog with multiorgan failure (7) (Table). Whether the 
newly identified parvoviruses play a role as canine patho-
gens has not yet been assessed.
We report the identification of a novel CPV. We de-
termined the genome sequence of the CPV and designed 
specific primers and probes useful for laboratory diagno-
sis. Screening of enteric and respiratory samples from dogs 
with either gastroenteric or respiratory disease and from 
animals without clinical signs suggested a possible asso-
ciation between the novel virus and respiratory disease in 
young dogs.
Material and Methods
Identification of the DNA of a Novel Parvovirus
In 2011, an outbreak of canine infectious respiratory 
disease (CIRD) occurred in a litter of 3 mixed-breed 
5-month-old puppies in Italy. The animals’ clinical signs 
were nasal discharge, coughing, and respiratory distress, 
but they completely recovered from the disease after 2 
weeks. Nasal and oropharyngeal swab specimens tested 
negative to a panel of molecular assays for CIRD-asso-
ciated common and emerging viral agents: canine adeno-
virus (CAV) types 1 and 2, canine distemper virus, canid 
herpesvirus 1 (CHV-1), canine respiratory coronavirus, 
influenza virus, canine parainfluenza virus, canine pneu-
movirus, nonprimate canine hepacivirus, B. bronchisep-
tica, Streptococcus equi subspecies zooepidemicus, and 
Mycoplasma cynos (12). Because the etiology of the out-
break was unknown, the case was considered eligible for 
metagenomic investigation. 
We performed random primed reverse transcription 
PCR and PCR assays on pooled samples (the nasal and 
oropharyngeal swab specimens of the 3 puppies) to am-
plify nucleic acids and used them as templates for next-
generation sequencing (NGS) experiments on the Ion Tor-
rent platform (New England Biolabs, Ipswich, MA, USA) 
(13). We evaluated sequence data using CLC Genomic 
Workbench (http://www.clcbio.com). NGS revealed the 
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presence of parvovirus-related sequence reads that mapped 
to human bufaviruses. We mapped a total of 3,530 reads to 
human bufavirus and assembled them into 3 contigs, 422-, 
416-, and 191-nt long. We reconstructed the nearly com-
plete genomic sequence of the new CPV (canine bufavirus 
[CBuV]), strain ITA/2011/297-15, by combining 5′ rapid 
amplification of cDNA ends (RACE) protocols (14) with 
minor modifications, using the kit 5′ RACE System for 
Rapid Amplification of cDNA Ends version 2.0 (Life Tech-
nologies, Paisley, UK) and a primer-walking strategy with 
specific primers designed to close the gaps among noncon-
tiguous sequences. We purified and cloned the amplicons 
using a TOPO XL Cloning Kit (Life Technologies) and 
generated consensus sequences by sequencing >3 clones 
for each PCR fragment.
Screening of Samples in Conventional and  
Quantitative PCR
We designed specific primers on the VP2 genomic re-
gion of strain ITA/2011/297-15 for quantitative detec-
tion in real-time PCR (qPCR) (CPPV-L3-for 5′ TGAA-
CAAGAAATAGACAACATTGTCAT 3′, CPPV-L3-rev 
5′ AAAGAGCAGTTAGGTCATTGTTGT 3′, and 
CPPV-L3 Pb 5′ Fam CCAAACAAGGTACAGGA-
CAGGAAGAAACAACACAA BHQ1 3′). We calcu-
lated CBuV DNA copy numbers on the basis of standard 
curves generated by 10-fold dilutions of a plasmid stan-
dard TOPO XL PCR containing a 500-nt fragment of the 
VP2 region of strain ITA/2011/297-15. We added 10 μL 
of sample DNA or plasmid standard to the 15-μL reaction 
master mix (IQ Supermix; Bio-Rad Laboratories SRL, 
Segrate, Italy) containing 0.6 μmol/L of each primer and 
0.2 μmol/L of probe. Thermal cycling consisted of activa-
tion of iTaq DNA polymerase at 95°C for 3 min, 42 cycles 
of denaturation at 95°C for 10 s, and annealing extension 
at 60°C for 30 s. We evaluated the specificity of the as-
say with a panel of canine DNA viruses (CPV-1, CPV-
2, CHV-1, circovirus, CAV-1, and CAV-2). The qPCR 
detected >101 DNA copies/10 μL of standard DNA and 
8.78 × 100 DNA copies/10 μL of DNA template extracted 
from clinical samples. CBuV quantification had an accept-
able level of repeatability over various magnitudes of target 
DNA concentrations, when calculating (15) the intraassay 
and interassay coefficients of variation within and between 
runs, respectively.
In addition, we designed specific primers (CPPV 165F 
5′ CTGGTTTAATCCAGCAGACT 3′ and CPPV 371R 5′ 
TGAAGACCAAGGTAGTAGGT 3′) to amplify and se-
quence a 207-nt fragment of VP2. We used the AccuPrime 
Taq DNA polymerase (Life Technologies) for PCR ampli-
fication. Cycling thermal conditions included initial activa-
tion of the polymerase at 94°C for 2 min, 45 cycles at 94°C 
for 30 s, 53°C for 30 s, and 72°C for 30 s, followed by final 
extension at 72°C for 10 min.
Respiratory Samples
During 2011–2015, we obtained nasal and oropharyngeal 
swab (NOP) samples from 58 pups and young dogs (<1 
year of age) with CIRD (collection RIS); the animals were 
early acute clinically ill CIRD dogs with onset of respira-
tory signs at 0–3 days at the time of sample collection. The 
RIS samples were a subset of a larger collection used for 
surveillance of traditional and emerging pathogens associ-
ated with CIRD (12). We collected samples from the nasal 
and oral cavities in parallel and stored them separately. We 
also screened NOP swabs obtained from 90 dogs <1 year 
of age without clinical signs (collection RIA) as controls. 
We collected all samples with dry swabs and immediately 
stored them at –20°C.
Enteric Samples
We screened archived enteric samples (stools and rectal 
swabs) collected at the Department of Veterinary Medicine, 
University of Bari, Italy, during 2010–2015 for CBuV. The 
samples had been obtained from pups and young dogs (<1 
year of age). We screened 81 samples from animals with 
 
Table. Parvoviruses identified in dogs and their classification and proposed classification of canine bufaviruses* 
Genus and species Common/used names in literature 
Year 
identified Place identified Reference 
GenBank 
accession no. 
Bocaparvovirus      
 Carnivore bocaparvovirus 1 CPV-1, minute virus of canines 
(MVC) or CBoV-1 
1970 United States (2) FJ214110 
 Carnivore bocaparvovirus 2 CBoV-1 or CBoV-2 2011 United States (6) JN648103 
 Carnivore bocaparvovirus 3 Feline bocaparvovirus 2009 United States (8) JQ692585 
 Carnivore bocaparvovirus 4† CBoV-3 2011 United States (7) KC580640 
Protoparvovirus      
 Carnivore protoparvovirus 1 CPV-2 1978 United States (4)  
 CPV-2a 1983 United States (9) M24000 
 CPV-2b 1984 United States (10) M74849 
 CPV-2c 2000 Italy (11) AY380577 
 Carnivore protoparvovirus 2† Canine bufavirus 2012–
2016 
Italy and 
Hungary 
This study MF198244–46 
*CBoV, canine bocavirus; CPV, canine parvovirus. 
†Candidate novel species. 
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signs of gastroenteritis (collection EIS) and 78 samples of 
animals without clinical signs (collection EIA).
We also searched for CBuV DNA in a collection of 
enteric samples from pups and young dogs (<1 year of age) 
either with gastroenteritis (collection EHS) or without clin-
ical signs of gastroenteritis (collection EHA), obtained in 
Hungary in 2012 and available at the Institute of Veterinary 
Medical Research, Hungarian Academy of Science, Buda-
pest. We screened 40 samples from healthy animals and 20 
samples from animals with clinical signs.
Statistical Analysis
We evaluated the associations among clinical signs, age, 
and presence of the virus in the respiratory and enteric sam-
ples by the χ2 test using a web-based software program (R 
version 3.3.0; http://www.r-project.org/). We set statistical 
significance at p<0.05.
Genome Analysis of Hungarian CBuV Strains
We selected samples positive for CBuV on the basis of 
the genome copies as revealed by quantitative PCR. We 
also identified the genomes of 2 additional CBuV strains, 
HUN/2012/22 and HUN/2012/126.
Sequence and Phylogenetic Analyses
We retrieved genome sequences of protoparvovirus strains 
from GenBank and aligned them using the Clustal Omega 
tool from the European Molecular Biology Laboratory 
(https://www.ebi.ac.uk/Tools/msa/clustalo/). We conduct-
ed sequence and phylogenetic analyses in Geneious ver-
sion 9.1.8 (Biomatters Ltd., Auckland, New Zealand); we 
used the neighbor-joining method, Jukes–Cantor genetic 
distance model, and bootstrapping for <1,000 replicates.
Virus Cultivation
We homogenized PCR-positive respiratory and fecal sam-
ples in 10% Dulbecco’s modified Eagle’s medium and then 
centrifuged them at 10,000 × g. We filtered the supernatant 
with 0.22-μm filters and inoculated it onto freshly seeded 
canine fibroblastic tumor (A-72) cells, incubated at 37°C in 
5% CO
2
. We also inoculated Madin-Darby canine kidney 
cell (MDCK) and Walter Reed canine cell (WRCC) lines. 
We evaluated viral growth through 5 serial passages, moni-
toring the onset of cellular cytopathic effect and testing the 
cell supernatant by qPCR.
Results
Genome Analysis of Canine Bufaviruses
We determined the nearly complete genome (4,537 nt) of 
the CBuV strain ITA/2011/297-15, including a partial 5′ 
untranslated region (UTR) (310 nt), the complete NS1 se-
quence (638 aa), the complete VP1 (710 aa) and VP2 (568 aa) 
sequences, and a partial 3′ UTR (8 nt). The genome cod-
ing sequence, excluding the terminal UTR regions, was 
4,219 nt (GenBank accession no. MF198244). The genome 
contained 2 major open reading frames (ORFs); the left 
ORF, coding for NS1, was 1,917 nt and the right ORF, en-
coding VP1 and VP2, was 2,316 nt (Figure 1, panel A). 
Full-genome sequence alignment showed a high degree of 
sequence divergence, up to 58% overall nucleotide iden-
tity to most parvoviruses but not bufaviruses. CBuV was 
more closely related to bufaviruses identified in primates 
(61.6%–63.2% nt similarity), pigs (59.6% nt), and bats 
(58% nt) (16–20) and more distantly related to CPV-2 
(45% nt) (online Technical Appendix Table, https://ww-
wnc.cdc.gov/EID/article/24/6/17-1965-Techapp1.pdf). 
The putative bufavirus NS1 start codon was located in a 
strong Kozak sequence, ACCATGG. The ATP- or GTP-
binding Walker loop motif (GXXXXGK[T/S]) was found 
in NS1 (405-GPASTGKS-412) (21). In addition, the NS1 
contained 2 conserved replication initiator motifs, GLHF-
HVLLQ and IVRYFLTKQP (boldface type indicates con-
served amino acids) (22). We generated an nt and aa se-
quence identity matrix. NS1 showed <69.4% nt and 51.4% 
aa identity with other parvovirus NS1 sequences, including 
its closest relatives in the Parvovirus genus (online Techni-
cal Appendix Table).
The termination of ORF1 overlapped the start of 
ORF2 by 14 nt. From sequence alignment and comparison 
with other BuVs, we detected 2 potential splice sites in 
the ORF1/ORF2 junction, a potential donor site (AG¯GT) 
at nt 1931 and an acceptor site (AG¯G) at nt 2115. The 
putative VP1 sequence started at the end of ORF1 at nt 
1906, upstream of the splice donor site at nt 1931 (Fig-
ure 1, panel B). We found the phospholipase A2 (PLA2) 
motif (Figure 1, panel A), with its highly conserved cal-
cium binding site (YLGPG), in the main ORF of VP1. 
The phospholipase catalytic residues (HD and D) were 
present at amino acid positions 41–42 and 63 (Figure 1, 
panel A). The VP1 showed <67.2% aa identity to other 
genera of the family Parvovirinae, including its closest 
relative in the Parvovirus genus (online Technical Appen-
dix Table). The N terminus of the CBuV VP2 protein con-
tained a glycine-rich sequence (GGGGGGGSGVG) that 
was also present in other parvoviral VP2 proteins (Figure 
1, panel A).
We successfully determined the complete coding ge-
nome sequence of 2 additional CBuV strains of enteric 
origin, HUN/2012/22 (GenBank accession no. MF198245) 
and HUN/2012/126 (GenBank accession no. MF198246); 
the sequence was 4,219 nt (4,463 and 4,308 nt with the 
partial UTRs, respectively). Overall, the 3 CBuV strains 
displayed 99.8%–99.9% nt identity to each other, with only 
1 nonsilent mutation in the NS1 protein and 1 nonsilent 
mutation in the VP2 protein.
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Upon phylogenetic analysis (Figure 2), the CBuV 
strains segregated into a well-defined group (bootstrap val-
ue 100), encompassing parvoviruses identified in rats, bats, 
pigs, and primates. The closest relatives within this group 
were parvoviruses from humans, commonly called human 
bufaviruses (16,17), and parvoviruses detected in monkeys 
(Macaca mulatta) (18) and pigs (19).
Screening in PCR of Canine Samples
Respiratory Samples
Molecular screening by qPCR detected CBuV DNA in 
10/58 (17.2%) oropharyngeal swabs and 15/58 (25.8%) 
nasal swabs from collection RIS. In total, 31% (18/58) of 
the animals tested positive for CBuV in either the pharyn-
geal or nasal sample, whereas 12.1% (7/58) were positive 
in both the oral and nasal swab sample. We did not de-
tect CBuV DNA in the NOP samples of the control group 
(0/90) (collection RIA). The viral loads of collection RIS 
ranged from 4.91 × 101 to 8.78 × 103 DNA copies/10 μL 
of template (mean 8.73 × 102 DNA copies; median 2.91 × 
102 DNA copies). We found a statistically significant dif-
ference for CBuV prevalence in oropharyngeal (odds ratio 
[OR] 6, 95% CI 1.6–23) and nasal (OR 10.1, 95% CI 2.7–
36.8) swab specimens when we compared animals with 
and without clinical signs (p<0.05 for both comparisons).
We reanalyzed the results by age-based cohorts of ani-
mals (0–6 and 7–12 months). In the 0–6-month group, only 
1/17 (5.8%) animals were positive; 17/41 (41.4%) tested 
positive in the 7–12-month group. However, this difference 
was not statistically significant (p>0.05).
We also screened the NOP swabs of the litter in-
fected by strain ITA/2011/297-15 in qPCR. We detected 
CBuV DNA in all 3 puppies, with viral titers as high as 
2.79 × 102, 1.01 × 103 DNA, and 3.77 × 103 copies/10 μL 
of template.
Enteric Samples
Molecular screening by qPCR revealed CBuV DNA in 
26/81 (32.1%) stools or rectal swabs from collection EIS 
Figure 1. Genome organization of canine bufavirus. A) Positions of the conserved helicase Walker A (GxxxxGKS), Walker B (EE), 
and replication initiator motifs (HuHuu and YuxK) in NS1 and of the phospholipase A2 (PLA2) and glycine-rich region (G-rich) in VP1 
and VP2. B) Putative splicing mechanism in the VP1 gene of canine bufavirus, human bufaviruses, and other protoparvoviruses. 
Two potential splice sites are a potential donor site (AG↓GT) at nt 1931 and an acceptor site (AG↓G) at nt 2115. The putative 
VP1 sequence starts with ATG at the end of ORF1 at nt 1906 upstream of the splice donor site at nt 1931. Gray shading indicates 
strictly and highly conserved bases. GenBank accession numbers are provided for reference sequences. NS, nonstructural; UTR, 
untranslated region; VP, viral capsid protein.
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Figure 2. Capsid-
based phylogenetic tree 
displaying the diversity 
of protoparvoviruses. 
The protoparvoviruses 
officially recognized by the 
International Committee 
on Taxonomy of Viruses 
are included, along 
with nonclassified (NC) 
protoparvoviruses. The tree 
was generated using the 
neighbor-joining method with 
the Jukes-Cantor algorithm 
of distance correction, with 
bootstrapping over 1,000 
replicates. Box indicates 
canine bufavirus strains. 
GenBank accession 
numbers are provided for 
reference isolates; gray 
fox amdovirus (GenBank 
accession no. JN202450) 
is used as outgroup. Scale 
bar indicates nucleotide 
substitutions per site. 
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and 15/78 (19.2%) samples of collection EIA. The viral 
loads of collection EIS ranged from 4.91 × 101 to 8.78 × 
103 DNA copies/10 μL of template (mean 4.21 × 102 DNA 
copies; median 1.38 × 102 DNA copies). The viral loads 
of collection EIA ranged from 5.10 × 101 to 4.34 × 102 
DNA copies per 10 μL of template (mean 1.76 × 102 DNA 
copies; median 1.48 × 102 DNA copies). We found no 
statistically significant difference between enteric signs 
and the presence of CBuV DNA in stools or rectal swabs.
We detected CBuV DNA in 8/20 (40%) enteric sam-
ples from collection EHS and 19/40 (47.5%) samples from 
collection EHA. The viral loads of collection EHS ranged 
from 1.31 × 101 to 5.42 × 103 DNA copies/10 μL of tem-
plate (mean 6.55 × 102 DNA copies; median 3.99 × 101 
DNA copies). The viral loads of collection EHA ranged 
from 1.21 × 101 to 2.57 × 1010 DNA copies/10 μL of tem-
plate (mean 1.35 × 109 DNA copies; median 2.92 × 102 
DNA copies). We found no statistically significant differ-
ence between enteric signs and the presence of CBuV DNA 
in the samples from Hungary.
We subjected samples containing genome copies >103 
DNA copies/10 μL of template to PCR amplification with 
primers CPPV 165F and CPPV 371R, which amplify a 
207-nt fragment of VP2. We successfully sequenced 12 
samples, yielding amplicons of the expected size in PCR 
and confirming the specificity of the qPCR.
Virus Cultivation
We visually inspected the inoculated monolayers of A-72, 
MDCK, and WRCC cells after 5 serial passages and moni-
tored virus titer in cellular supernatant by qPCR. We did 
not observe viral growth in any of the cells. 
Discussion
We report the detection and genomic characterization of 
CBuV, a novel canine protoparvovirus, from a small out-
break of CIRD. In the NS1 gene, CBuV displayed low 
nt (24.1%–69.4%) and aa (19.3%–51.4%) identities com-
pared with other protoparvoviruses. Current International 
Committee on Taxonomy of Viruses criteria for classifi-
cation of parvoviruses into the same species require >85% 
aa identity in the NS1 protein; on this basis, CBuV could 
be classified as a new parvovirus species. The closest rela-
tives to CBuV were protoparvoviruses identified in pri-
mates and other mammals (16–19), commonly termed as 
bufaviruses. Bufaviruses were first identified in 2012 in 
Burkina Faso in fecal samples from a child with enteric 
signs (16). Similar bufaviruses have been subsequently 
identified in different species of domestic and wild ani-
mals (18–20). CBuV exhibited the most similarity in NS1 
(66.9%–69.4% nt and 47.2%–51.4% aa) and VP1 (66%–
68.2% nt and 62.5%–67.2% aa) to bufaviruses identified 
in primates. In addition, the genetic organization of CBuV 
resembled that of primate bufaviruses, with the conser-
vation of a potential splicing mechanism regulating VP1 
translation. On the other hand, CBuV was genetically 
more distantly related to CPV-2, showing only 56% nt 
and 40.6% aa identity in the NS1 and 42.6% nt and 33.4% 
aa identity in the VP1 between the 2 canine protoparvo-
viruses. Because we were not able to adapt the virus to in 
vitro growth in different canine cell lines, we could not 
assess whether there is an antigenic relationship between 
the 2 canine protoparvoviruses, CBuV and CPV-2, in 
cross-neutralization studies.
A small case–control study on samples of enteric and 
respiratory origin in puppies and young dogs (<1 year of 
age) revealed that CBuV appeared significantly more com-
mon in NOP swab samples from dogs with acute CIRD. 
We detected CBuV DNA in 17.2% (10/58) of oropharyn-
geal swab specimens and 25.8% (15/58) of nasal swab 
specimens from collection RIS. In total, 31% (18/58) of 
the animals with CIRD tested positive for CBuV, whereas 
the virus was not detectable in respiratory samples of 90 
animals without clinical signs. When we analyzed the 
results of collection RIS by age-based cohorts, we ob-
served an increased prevalence (41.4%, 17/41) in the 7- to 
12-month age group, whereas only 1/17 animals (5.8%) 
in the 0- to 6-month age group tested positive for CBuV. 
We also found a high prevalence of CBuV DNA in canine 
stool samples, although we observed no substantial dif-
ference between dogs with enteric disease and clinically 
healthy dogs. These findings indicate that CBuVs are a 
common component of the canine fecal virome.
With certain exceptions, it has been difficult to demon-
strate a clear association of many potential pathogens with 
CIRD in either epidemiologic studies or experimental in-
fections. Our study could not provide conclusive evidence 
for a role of this novel virus in CIRD.
CIRD or kennel cough has a multiagent etiology, with 
>1 agent (viruses or bacteria) involved sequentially or syn-
ergistically to cause disease (23). Pathogens commonly as-
sociated with CIRD include CAV-2, canine parainfluenza 
virus, and Bordetella bronchiseptica (12,24,25). Less com-
monly, CHV-1 can cause respiratory disease (26). CAV-1 
and canine distemper virus infections are also associated 
with respiratory disease but are usually responsible for sys-
temic disease (26,27).
In recent years, other emerging agents have been as-
sociated with CIRD, including canine respiratory corona-
virus (27,28), canine pneumovirus (29), nonprimate canine 
hepacivirus (30), CBoVs (6), Mycoplasma cynos (31), 
and Streptococcus equi subsp. zooepidemicus (32,33). In 
addition, thus far, >5 strains of influenza virus have been 
identified in dogs: the equine-derived H3N8 virus, the 
human-derived H1N1 virus, and the avian-like H3N2, 
H3N1, and H5N2 viruses (34,35).
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Of interest, the titer of CBuV in the NOP samples was 
not high, with a median value of 2.91 × 102 DNA copies/10 
μL. This low level of virus shedding in NOP secretions was 
difficult to interpret, and intrinsic properties of the virus, or 
the dynamics of virus shedding at the time of sampling, or 
both could account for it. For comparison, a human parvo-
virus associated with respiratory disease, human bocapar-
vovirus 1, can be shed at titers as high as 3.9 × 1011 copies/
mL in NOP samples (36). It is worth noting that we also 
found high loads of CBuV (<2.57 × 1010 DNA copies/10 
μL of template) in 4 fecal samples that substantially ex-
ceeded the median value (2.92 × 102 DNA copies/10 μL) 
of collection EHA.
To date, scientists have searched for bufaviruses al-
most exclusively in fecal samples and have detected them 
in diarrheal stools of patients of all ages worldwide. The 
prevalence of bufaviruses in human patients ranges from 
0.3% to 4%, and their etiologic role in enteric or ex-
traenteric diseases remains uncertain (16,17,37–41). Bu-
faviruses have also been found in other mammalian hosts, 
including wild and captive nonhuman primates, swine, 
shrews, rats, bats, and fur seals (18–20,42–46). Of inter-
est, bufaviruses have also been detected in the serum and 
spleens of monkeys and in the spleens of shrews (18,44) 
and in a unique NOP sample of 955 human patients with 
lower respiratory tract signs (47), suggesting the pos-
sibility of extraintestinal or systemic infections. In this 
study, we have also reconstructed the genome sequence 
of 2 CBuV strains detected in canine fecal samples. By 
genome comparison, we observed only 2 aa differences 
between the CBuV strains of respiratory and enteric ori-
gin, although the viruses were identified from animals 
of different geographic origin (i.e., Italy and Hungary). 
Although our findings corroborate earlier evidence that 
bufaviruses can target extraintestinal tissues and organs, 
only animal experiments or detailed observational studies 
can fully address this issue.
In conclusion, the advancement of techniques 
available for pathogen discovery is quickly broadening 
the list of potential canine infectious agents. Under-
standing in more depth the effects of those agents on 
canine health will be pivotal to implementing future 
strategies for prophylaxis, chiefly for complex diseases 
like CIRD.
Acknowledgments
We thank L.E. Carmichael for reading and critical revision of  
the manuscript. 
Financial support was obtained from the grant IZS PB 2/15 RC 
by the Italian Ministry of Health and the Momentum Program 
awarded by the Hungarian Academy of Sciences. S.M. was the 
recipient of the Bolyai scholarship. 
About the Author
Dr. Martella is a full professor in the Department of Veterinary 
Medicine, University of Bari, Italy. His research is focused on 
diagnosis, epidemiology, and characterization of human and 
animal viruses, with particular interest in zoonotic viruses.
References
  1. Cotmore SF, Agbandje-McKenna M, Chiorini JA, Mukha DV, 
Pintel DJ, Qiu J, et al. The family Parvoviridae. Arch Virol. 
2014;159:1239–47. http://dx.doi.org/10.1007/s00705-013-1914-1
  2. Binn LN, Lazar EC, Eddy GA, Kajima M. Recovery and  
characterization of a minute virus of canines. Infect Immun. 
1970;1:503–8.
  3. Decaro N, Amorisco F, Lenoci D, Lovero A, Colaianni ML, 
Losurdo M, et al. Molecular characterization of canine minute  
virus associated with neonatal mortality in a litter of Jack  
Russell terrier dogs. J Vet Diagn Invest. 2012;24:755–8.  
http://dx.doi.org/10.1177/1040638712445776
  4. Appel MJG, Scott FW, Carmichael LE. Isolation and immunisation 
studies of a canine parco-like virus from dogs with haemorrhagic 
enteritis. Vet Rec. 1979;105:156–9. http://dx.doi.org/10.1136/
vr.105.8.156
  5. Decaro N, Buonavoglia C. Canine parvovirus—a review of  
epidemiological and diagnostic aspects, with emphasis on type 2c. 
Vet Microbiol. 2012;155:1–12. http://dx.doi.org/10.1016/ 
j.vetmic.2011.09.007
  6. Kapoor A, Mehta N, Dubovi EJ, Simmonds P, Govindasamy L, 
Medina JL, et al. Characterization of novel canine bocaviruses  
and their association with respiratory disease. J Gen Virol. 
2012;93:341–6. http://dx.doi.org/10.1099/vir.0.036624-0
  7. Li L, Pesavento PA, Leutenegger CM, Estrada M, Coffey LL, 
Naccache SN, et al. A novel bocavirus in canine liver. Virol J. 
2013;10:54. http://dx.doi.org/10.1186/1743-422X-10-54
  8. Lau SK, Woo PC, Yeung HC, Teng JL, Wu Y, Bai R, et al.  
Identification and characterization of bocaviruses in cats and  
dogs reveals a novel feline bocavirus and a novel genetic  
group of canine bocavirus. J Gen Virol. 2012;93:1573–82.  
http://dx.doi.org/10.1099/vir.0.042531-0
  9. Parrish CR, O’Connell PH, Evermann JF, Carmichael LE.  
Natural variation of canine parvovirus. Science. 1985;230:1046–8. 
http://dx.doi.org/10.1126/science.4059921
10. Parrish CR, Aquadro CF, Strassheim ML, Evermann JF, Sgro JY, 
Mohammed HO. Rapid antigenic-type replacement and DNA 
sequence evolution of canine parvovirus. J Virol. 1991;65:6544–52.
11. Buonavoglia C, Martella V, Pratelli A, Tempesta M, Cavalli A, 
Buonavoglia D, et al. Evidence for evolution of canine  
parvovirus type 2 in Italy. J Gen Virol. 2001;82:3021–5.  
http://dx.doi.org/10.1099/0022-1317-82-12-3021
12. Decaro N, Mari V, Larocca V, Losurdo M, Lanave G, Lucente MS, 
et al. Molecular surveillance of traditional and emerging pathogens 
associated with canine infectious respiratory disease. Vet Microbiol. 
2016;192:21–5. http://dx.doi.org/10.1016/j.vetmic.2016.06.009
13. Mihalov-Kovács E, Gellért Á, Marton S, Farkas SL, Fehér E,  
Oldal M, et al. Candidate new rotavirus species in sheltered dogs, 
Hungary. Emerg Infect Dis. 2015;21:660–3. http://dx.doi.org/ 
10.3201/eid2104.141370
14. Scotto-Lavino E, Du G, Frohman MA. 5′ end cDNA  
amplification using classic RACE. Nat Protoc. 2006;1:2555–62. 
http://dx.doi.org/10.1038/nprot.2006.480
15. Decaro N, Amorisco F, Desario C, Lorusso E, Camero M,  
Bellacicco AL, et al. Development and validation of a real-time 
PCR assay for specific and sensitive detection of canid herpesvirus 
1. J Virol Methods. 2010;169:176–80. http://dx.doi.org/10.1016/ 
j.jviromet.2010.07.021
RESEARCH
1068 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 6, June 2018
16. Phan TG, Vo NP, Bonkoungou IJ, Kapoor A, Barro N, O’Ryan M,  
et al. Acute diarrhea in West African children: diverse enteric 
viruses and a novel parvovirus genus. J Virol. 2012;86:11024–30. 
http://dx.doi.org/10.1128/JVI.01427-12
17. Yahiro T, Wangchuk S, Tshering K, Bandhari P, Zangmo S,  
Dorji T, et al. Novel human bufavirus genotype 3 in children  
with severe diarrhea, Bhutan. Emerg Infect Dis. 2014;20:1037–9. 
http://dx.doi.org/10.3201/eid2006.131430
18. Handley SA, Thackray LB, Zhao G, Presti R, Miller AD, Droit L, 
et al. Pathogenic simian immunodeficiency virus infection is  
associated with expansion of the enteric virome. Cell. 
2012;151:253–66. http://dx.doi.org/10.1016/j.cell.2012.09.024
19. Hargitai R, Pankovics P, Kertész AM, Bíró H, Boros Á, Phan TG, 
et al. Detection and genetic characterization of a novel parvovirus 
distantly related to human bufavirus in domestic pigs. Arch Virol. 
2016;161:1033–7. http://dx.doi.org/10.1007/s00705-015-2732-4
20. Sasaki M, Gonzalez G, Wada Y, Setiyono A, Handharyani E, 
Rahmadani I, et al. Divergent bufavirus harboured in megabats 
represents a new lineage of parvoviruses. Sci Rep. 2016;6:24257. 
http://dx.doi.org/10.1038/srep24257
21. Walker JE, Saraste M, Runswick MJ, Gay NJ. Distantly related 
sequences in the alpha- and beta-subunits of ATP synthase, myosin, 
kinases, and other ATP-requiring enzymes and a common  
nucleotide binding fold. EMBO J. 1982;1:945–51.
22. Phan TG, Sdiri-Loulizi K, Aouni M, Ambert-Balay K, Pothier P, 
Deng X, et al. New parvovirus in child with unexplained  
diarrhea, Tunisia. Emerg Infect Dis. 2014;20:1911–3.  
http://dx.doi.org/10.3201/eid2011.140428
23. Buonavoglia C, Martella V. Canine respiratory viruses. Vet Res. 
2007;38:355–73. http://dx.doi.org/10.1051/vetres:2006058
24. Joffe DJ, Lelewski R, Weese JS, Mcgill-Worsley J, Shankel C, 
Mendonca S, et al. Factors associated with development of canine 
infectious respiratory disease complex (CIRDC) in dogs in 5  
Canadian small animal clinics. Can Vet J. 2016;57:46–51.
25. Schulz BS, Kurz S, Weber K, Balzer HJ, Hartmann K. Detection 
of respiratory viruses and Bordetella bronchiseptica in dogs with 
acute respiratory tract infections. Vet J. 2014;201:365–9.  
http://dx.doi.org/10.1016/j.tvjl.2014.04.019
26. Decaro N, Martella V, Buonavoglia C. Canine adenoviruses and 
herpesvirus. Vet Clin North Am Small Anim Pract. 2008;38:799–
814, viii. http://dx.doi.org/10.1016/j.cvsm.2008.02.006
27. Decaro N, Desario C, Elia G, Mari V, Lucente MS, Cordioli P, et al. 
Serological and molecular evidence that canine respiratory  
coronavirus is circulating in Italy. Vet Microbiol. 2007;121:225–30. 
http://dx.doi.org/10.1016/j.vetmic.2006.12.001
28. Erles K, Toomey C, Brooks HW, Brownlie J. Detection of  
a group 2 coronavirus in dogs with canine infectious respiratory 
disease. Virology. 2003;310:216–23. http://dx.doi.org/10.1016/
S0042-6822(03)00160-0
29. Renshaw RW, Zylich NC, Laverack MA, Glaser AL, Dubovi EJ. 
Pneumovirus in dogs with acute respiratory disease. Emerg Infect 
Dis. 2010;16:993–5. http://dx.doi.org/10.3201/eid1606.091778
30. Kapoor A, Simmonds P, Gerold G, Qaisar N, Jain K, Henriquez JA, 
et al. Characterization of a canine homolog of hepatitis  
C virus. Proc Natl Acad Sci U S A. 2011;108:11608–13.  
http://dx.doi.org/10.1073/pnas.1101794108
31. Chalker VJ, Owen WM, Paterson C, Barker E, Brooks H,  
Rycroft AN, et al. Mycoplasmas associated with canine  
infectious respiratory disease. Microbiology. 2004;150:3491–7. 
http://dx.doi.org/10.1099/mic.0.26848-0
32. Chalker VJ, Brooks HW, Brownlie J. The association of  
Streptococcus equi subsp. zooepidemicus with canine infectious 
respiratory disease. Vet Microbiol. 2003;95:149–56.  
http://dx.doi.org/10.1016/S0378-1135(03)00155-X
33. Priestnall SL, Erles K, Brooks HW, Cardwell JM, Waller AS,  
Paillot R, et al. Characterization of pneumonia due to  
Streptococcus equi subsp. zooepidemicus in dogs. Clin Vaccine  
Immunol. 2010;17:1790–6. http://dx.doi.org/10.1128/ 
CVI.00188-10
34. Crawford PC, Dubovi EJ, Castleman WL, Stephenson I, Gibbs EP, 
Chen L, et al. Transmission of equine influenza virus to dogs.  
Science. 2005;310:482–5. http://dx.doi.org/10.1126/science.1117950
35. Zhu H, Hughes J, Murcia PR. Origins and evolutionary dynamics 
of H3N2 canine influenza virus. J Virol. 2015;89:5406–18.  
http://dx.doi.org/10.1128/JVI.03395-14
36. Zhou L, Zheng S, Xiao Q, Ren L, Xie X, Luo J, et al. Single  
detection of human bocavirus 1 with a high viral load in severe  
respiratory tract infections in previously healthy children. BMC 
Infect Dis. 2014;14:424. http://dx.doi.org/10.1186/1471-2334-14-424
37. Väisänen E, Kuisma I, Phan TG, Delwart E, Lappalainen M, 
Tarkka E, et al. Bufavirus in feces of patients with gastroenteritis,  
Finland. Emerg Infect Dis. 2014;20:1077–9. http://dx.doi.org/ 
10.3201/eid2006.131674
38. Smits SL, Schapendonk CM, van Beek J, Vennema H,  
Schürch AC, Schipper D, et al. New viruses in idiopathic human  
diarrhea cases, the Netherlands. Emerg Infect Dis. 2014;20:1218–
22. http://dx.doi.org/10.3201/eid2007.140190
39. Chieochansin T, Vutithanachot V, Theamboonlers A, Poovorawan Y.  
Bufavirus in fecal specimens of patients with and without  
diarrhea in Thailand. Arch Virol. 2015;160:1781–4.  
http://dx.doi.org/10.1007/s00705-015-2441-z
40. Altay A, Yahiro T, Bozdayi G, Matsumoto T, Sahin F, Ozkan S,  
et al. Bufavirus genotype 3 in Turkish children with severe  
diarrhoea. Clin Microbiol Infect. 2015;21:965.e1–4.  
http://dx.doi.org/10.1016/j.cmi.2015.06.006
41. Huang DD, Wang W, Lu QB, Zhao J, Guo CT, Wang HY, et al. 
Identification of bufavirus-1 and bufavirus-3 in feces of  
patients with acute diarrhea, China. Sci Rep. 2015;5:13272.  
http://dx.doi.org/10.1038/srep13272
42. Yang S, Liu D, Wang Y, Qu F, He Y, Sun Z, et al. Bufavirus 
Protoparvovirus in feces of wild rats in China. Virus Genes. 
2016;52:130–3. http://dx.doi.org/10.1007/s11262-015-1262-1
43. Kluge M, Campos FS, Tavares M, de Amorim DB, Valdez FP, 
Giongo A, et al. Metagenomic survey of viral diversity obtained 
from feces of subantarctic and South American fur seals.  
PLoS One. 2016;11:e0151921. http://dx.doi.org/10.1371/ 
journal.pone.0151921
44. Sasaki M, Orba Y, Anindita PD, Ishii A, Ueno K, Hang’ombe BM, 
et al. Distinct lineages of bufavirus in wild shrews and  
nonhuman primates. Emerg Infect Dis. 2015;21:1230–3.  
http://dx.doi.org/10.3201/eid2107.141969
45. Liu L, Schwarz L, Ullman K, Ahola H, Qiu Y, Ma Z, et al.  
Identification of a novel bufavirus in domestic pigs by a viral 
metagenomic approach. J Gen Virol. 2016;97:1592–6.  
http://dx.doi.org/10.1099/jgv.0.000476
46. Kemenesi G, Dallos B, Görföl T, Estók P, Boldogh S, Kurucz K, 
et al. Genetic diversity and recombination within bufaviruses: 
detection of a novel strain in Hungarian bats. Infect Genet Evol. 
2015;33:288–92. http://dx.doi.org/10.1016/j.meegid.2015.05.017
47. Väisänen E, Paloniemi M, Kuisma I, Lithovius V, Kumar A, 
Franssila R, et al. Epidemiology of two human protoparvoviruses, 
bufavirus and tusavirus. Sci Rep. 2016;6:39267. http://dx.doi.org/ 
10.1038/srep39267
Address for correspondence: Vito Martella, Dipartimento di Medicina 
Veterinaria, Università Aldo Moro di Bari, S.p. per Casamassima,  
Km 3- 70010, Valenzano, Bari, Italy; email: vito.martella@uniba.it
